Neurophet, a brain imaging company, recently secured 32 billion won ($21.5 million) in institutional investment, according to KBR. This capital injection fuels a neuroimaging sector valued at USD 37.63 billion in 2023, projected to surpass USD 56.58 billion by 2030, according to biospace. Significant expansion in medical diagnostics and research is signaled by such growth.
The neuroimaging market is undeniably expanding at a rapid pace, but leading research firms present vastly different current valuations and future projections for its size. An opaque landscape for strategic planning is created by this discrepancy, despite the clear influx of capital.
While the overall growth trajectory for brain imaging technology is clear, stakeholders must carefully evaluate specific market segments and their respective growth drivers to navigate the diverse landscape of neuroimaging opportunities.
The Current Landscape of Neuroimaging Growth
The neuroimaging market is expected to grow at a Compound Annual Growth Rate (CAGR) of 6% from 2023 to 2030, according to biospace. A robust sector is confirmed by this sustained expansion.
North America accounted for over 39% of revenue share in 2025, according to Precedence Research. Market penetration and adoption are heavily concentrated due to this regional dominance, indicating either significant barriers to entry elsewhere or substantial untapped potential in other geographies.
Brain Imaging Devices: A Specialized Growth Engine
The global brain imaging devices market is projected to grow from approximately USD 5 billion in 2024 to around USD 7.7 billion by 2032, with a compound annual growth rate of 5.50% to 6%, according to Research and Markets. Grand View Research projects a higher CAGR of 8.2% from 2025 to 2030 for this segment. While both sources confirm growth, the variance in CAGR highlights the difficulty in precisely forecasting even specific sub-segments.
The stark difference between the projected $56.58 billion neuroimaging market (biospace) and the $9.03 billion brain imaging devices market (Grand View Research) by 2030 reveals that the real value and future growth lie predominantly in software, AI, and services layered on top of hardware, rather than in the devices themselves.
Navigating Discrepant Market Valuations
Precedence Research valued the global brain imaging and neuroimaging market at USD 15.84 billion in 2025. In stark contrast, biospace valued the global neuroimaging market at USD 37.63 billion in 2023. A fundamental lack of consensus on the market's current scale is underscored by this significant disparity, exceeding $20 billion over a two-year span.
Strategic planning and investment decisions are being made without a clear, universally agreed-upon understanding of the market's true scale due to this over $20 billion discrepancy in current market valuations. Companies navigating the neuroimaging space are operating with a critical blind spot.
Future Trajectories and Unlocking Potential
Despite the valuation discrepancies, both the broader neuroimaging market and its device segment show consistent growth trajectories. The global neuroimaging market is projected to surpass USD 56.58 billion by 2030 (biospace), while brain imaging devices are projected to reach USD 9.03 billion by 2030 (Grand View Research). A market ripe for innovation, particularly in value-added services built upon the hardware, is indicated by this sustained expansion, with CAGRs of 6% and 8.2% respectively.
Given the substantial capital inflows and consistent growth projections, the neuroimaging market appears poised for continued expansion, though its true scale and the most lucrative opportunities will likely remain fragmented across specialized software and service innovations rather than solely in hardware.
